Aurobindo Receives FDA Approval for Emtricitabine Capsules, 200 mg
Published: March 15, 2023
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Emtricitabine Capsules, 200 mg. Aurobindo Pharma’s Emtricitabine Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Emtriva® (emtricitabine) Capsules manufactured by Gilead Sciences, Inc.
Emtricitabine Capsules are indicated in:
- Combination with other antiretroviral agents, for the treatment of HIV-1 infection.